Vijai Simha

A randomized phase 3 trial comparing nimotuzumab plus cisplatin chemoradiotherapy versus cisplatin chemoradiotherapy alone in locally advanced head and neck cancer

Vijay Patil, Vanita Noronha, Amit Joshi et al. · Cancer · 2019 · 127 citations

Low-cost oral metronomic chemotherapy versus intravenous cisplatin in patients with recurrent, metastatic, inoperable head and neck carcinoma: an open-label, parallel-group, non-inferiority, randomised, phase 3 trial

Vijay Patil, Vanita Noronha, Sachin Dhumal et al. · The Lancet Global Health · 2020 · 98 citations · Full text

Phase I/II Study of Palliative Triple Metronomic Chemotherapy in Platinum-Refractory/Early-Failure Oral Cancer

Vijay Patil, Vanita Noronha, Amit Joshi et al. · Journal of Clinical Oncology · 2019 · 74 citations

Outcomes in non-metastatic treatment naive extremity osteosarcoma patients treated with a novel non-high dosemethotrexate-based, dose-dense combination chemotherapy regimen ‘OGS-12’

Jyoti Bajpai, Arun Chandrasekharan, Vikas Talreja et al. · European Journal of Cancer · 2017 · 55 citations

Surgical Oncology, Oncology, Metronomic Therapy +5

Stepwise cox regression analysis in SPSS

Vijay Patil, Sampada Dessai, Vijai Simha · Cancer Research Statistics and Treatment · 2018 · 55 citations · Full text

Nursing, Patient Safety, Cox Analysis +7